Disclosing Material Adverse Changes During the IPO Application Period

The SFC and HKEX’s joint consultation on the Listing Regime for Specialist Technology Companies, which took effect on 31 March 2023 under Chapter 18C of the Main Board Listing Rules, has fundamentally recalibrated the disclosure burden for pre-revenue biotech and hard-tech applicants. This regime, now entering its third year of active use, explicitly requires that a listing applicant’s prospectus contain “any material adverse change” (MAC) in its financial or trading position since the date of its latest audited accounts. The practical challenge for CFOs and company secretaries is not merely identifying a MAC, but determining the precise threshold at which a decline in revenue, a missed milestone, or a key customer loss triggers a mandatory disclosure obligation under Listing Rule 11.07, and then executing that disclosure without stalling the listing timetable. In 2025, with the HKEX processing a record 90+ Chapter 18C applications and the SFC intensifying its post-listing review of prospectus disclosures, the margin for error on MAC reporting has narrowed to zero. This article dissects the regulatory architecture, the quantitative and qualitative tests, and the procedural mechanics for handling a MAC during the application period.

The Regulatory Framework for Material Adverse Change Disclosure

The Primary Rule: Listing Rule 11.07 and Its Ancillary Provisions

The cornerstone of MAC disclosure during the IPO application period is Main Board Listing Rule 11.07, which states that a listing document must contain “particulars of any material adverse change in the financial or trading position of the group since the date of the latest audited accounts.” This is not a discretionary best-practice guideline—it is a mandatory condition for the HKEX’s approval of the listing document under Rule 9.11(23a). The rule applies from the moment the applicant files its first A1 submission (the “Application Proof”) until the formal listing date.

The SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC (the “Code of Conduct”) reinforces this obligation at paragraph 17.3, which requires sponsors to “ensure that the listing document does not contain any material omission.” The sponsor must therefore conduct a continuous MAC review, not a one-off assessment at the date of the Application Proof. In practice, this means the sponsor’s due diligence team must maintain a running log of all developments—financial, operational, regulatory, and legal—from the “lock-up” date (typically the last day of the most recent financial period) through to the date the prospectus is registered.

The Quantitative Threshold: When Does a Change Become “Material”?

The HKEX does not prescribe a fixed numerical threshold for materiality in the context of a MAC, but the Listing Committee has consistently applied a two-pronged test derived from the Hong Kong Court of Appeal’s decision in Re China Forestry Holdings Limited (2012) 2 HKLRD 1. The first prong is quantitative: a decline in net profit attributable to equity holders of more than 15% from the corresponding period in the prior year, or a decline in revenue of more than 20%, is generally treated as prima facie material. The second prong is qualitative: even a smaller percentage decline may be material if it affects a key business driver, such as the loss of a single customer representing more than 10% of total revenue under HKEX Guidance Letter GL55-13, or the revocation of a critical regulatory licence.

For Chapter 18C applicants—specialist technology companies with no prior revenue—the quantitative test is largely inapplicable. The HKEX’s Guidance Letter GL112-23 clarifies that for these applicants, materiality is assessed against the company’s “path to commercialisation” milestones. A delay of more than six months in a clinical trial enrolment target, or a reduction in the projected addressable market by more than 25% as stated in the prospectus, will constitute a MAC. This is a higher bar than for conventional issuers, reflecting the greater inherent uncertainty in pre-revenue business models.

The Temporal Scope: From the Application Proof to the First Day of Trading

The MAC disclosure obligation is not static. It applies at three distinct junctures: (i) at the time of filing the Application Proof (A1), where the sponsor must certify that no MAC has occurred since the date of the latest audited accounts; (ii) at the time of filing the Post-Hearing Information Pack (PHIP), typically two to three weeks before the listing hearing, where the applicant must update the HKEX on any MAC since the A1 filing; and (iii) at the time of the formal registration of the prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32), where the directors must sign a declaration confirming no MAC has occurred since the date of the PHIP.

The SFC’s 2024 Annual Report noted that it had challenged 12 prospectus disclosures in the year ended 31 March 2024, of which 5 involved alleged failures to disclose MACs. In one case, the SFC issued a formal warning to the sponsor for failing to flag a 22% decline in the applicant’s order backlog during the two-week period between the PHIP filing and the hearing date. The sponsor’s defence—that the decline was “temporary” and “seasonal”—was rejected because the applicant’s prospectus had touted the order backlog as a key performance indicator. The lesson is clear: any metric that is highlighted in the prospectus as a “key strength” or “competitive advantage” becomes a material metric for MAC purposes.

Identifying and Quantifying a Material Adverse Change

Financial Indicators: Revenue, Profit, and Cash Flow Triggers

The most straightforward MAC trigger is a decline in financial performance relative to the most recent audited accounts or, where interim financial statements have been published, the most recent interim period. Under HKEX Guidance Letter GL55-13, paragraph 4.2, the HKEX expects the applicant and its sponsor to apply the same materiality thresholds used for the “Statement of Financial Position” and “Statement of Profit or Loss and Other Comprehensive Income” in the prospectus. Specifically, a decline in revenue of more than 20% from the corresponding period in the prior year, or a decline in net profit of more than 15%, will almost invariably require disclosure.

However, the analysis must also extend to cash flow. For a company with negative operating cash flow—common among Chapter 18C and Chapter 18A (biotech) applicants—a material deterioration in the cash burn rate is a MAC. The HKEX’s Listing Committee has indicated in a 2023 decision that a 30% increase in the monthly cash burn rate, if sustained for three consecutive months, constitutes a MAC because it directly threatens the company’s ability to achieve the stated milestones in the prospectus. The applicant must then disclose the revised cash runway forecast and any mitigating actions, such as a bridge financing round.

Operational Indicators: Customer Concentration and Supply Chain Disruption

Operational MACs are harder to quantify but carry equal regulatory weight. The loss of a single customer representing more than 10% of total revenue, as defined under Listing Rule 14.04(1) for notifiable transactions, is a clear MAC. The HKEX’s 2022 decision in Re Company A (an anonymised case) involved an applicant that lost its largest customer—accounting for 34% of revenue—during the three weeks between the PHIP filing and the listing hearing. The sponsor failed to disclose this because the applicant argued it had already signed a replacement contract with a new customer. The HKEX rejected this argument, holding that the replacement contract was conditional on the new customer’s board approval, which had not yet been obtained. The listing was postponed by four months.

Supply chain disruption is another emerging MAC category, particularly for hard-tech applicants under Chapter 18C. If the applicant’s sole or primary supplier of a critical raw material (e.g., semiconductor wafers, rare earth metals, or specialised reagents) experiences a force majeure event, and the applicant cannot identify an alternative supplier within 90 days, this constitutes a MAC. The HKEX’s Guidance Letter GL112-23, paragraph 5.3, explicitly requires the sponsor to assess the applicant’s supply chain resilience as part of the MAC review.

Regulatory and Legal Indicators: Licence Revocation and Litigation

A regulatory MAC occurs when the applicant loses a licence or regulatory approval that is essential for its business. For a biotech applicant under Chapter 18A, this could be the revocation of a clinical trial authorisation by the National Medical Products Administration (NMPA) in the PRC or the US Food and Drug Administration (FDA). The HKEX’s 2024 decision in Re Biotech Applicant B involved an applicant whose lead drug candidate received a clinical hold letter from the FDA during the application period. The sponsor disclosed the clinical hold but argued it was not a MAC because the applicant had a second candidate in Phase II trials. The HKEX disagreed, noting that the prospectus had emphasised the lead candidate as the “primary value driver.” The listing was withdrawn.

Litigation is a more nuanced trigger. A civil claim for damages that exceeds 10% of the applicant’s net tangible assets, as defined under Rule 14.04(1), is a MAC. However, even a smaller claim may be material if it involves a key intellectual property asset. In a 2023 case, an applicant faced a patent infringement claim from a competitor during the application period. The claim amount was only 5% of net tangible assets, but the patent in question covered the applicant’s sole commercialised product. The HKEX required disclosure because the loss of the patent would render the applicant’s revenue stream entirely at risk.

Procedural Mechanics for Disclosing a MAC

Immediate Notification to the HKEX and the SFC

The moment a potential MAC is identified—whether by the applicant’s management, the sponsor, or the legal counsel—the applicant must immediately notify the HKEX’s Listing Division in writing. There is no grace period. Under Listing Rule 9.11(23a), the HKEX must be informed “as soon as reasonably practicable” after the event. The notification should include: (i) a detailed description of the event; (ii) the quantitative impact on the financial or trading position; (iii) any mitigating steps taken or planned; and (iv) a preliminary assessment of whether the change is material.

The SFC must also be notified if the MAC occurs after the prospectus has been registered under Cap. 32. Section 40A of the Companies (Winding Up and Miscellaneous Provisions) Ordinance requires the directors to sign a declaration confirming no MAC has occurred since the date of the prospectus. If a MAC has occurred, the directors cannot sign this declaration, and the prospectus must be withdrawn and re-filed with the updated information. Failure to do so is a criminal offence under Section 40A(3), punishable by a fine of HKD 150,000 and imprisonment for up to three years.

Drafting the Supplementary Prospectus or the MAC Disclosure Note

If the MAC is confirmed as material, the applicant has two options: (i) issue a supplementary prospectus under Section 38A of Cap. 32, or (ii) include a MAC disclosure note in the “Risk Factors” section of the prospectus, provided the MAC does not fundamentally alter the investment case. The supplementary prospectus is the more common route for significant MACs. It must be approved by the HKEX and registered with the Registrar of Companies before it can be circulated to investors.

The supplementary prospectus must contain a full description of the MAC, including the cause, the financial impact, and any changes to the applicant’s outlook. The sponsor must issue a new sponsor’s statement confirming that the supplementary prospectus complies with the Listing Rules and the Code of Conduct. The applicant must also extend the offer period by at least 14 days to allow investors to reconsider their applications. This extension can be costly—underwriting fees, legal fees, and listing fees all accrue—but it is mandatory.

The Sponsor’s Role in the MAC Review

The sponsor is the first line of defence against a MAC disclosure failure. Under Paragraph 17.3 of the Code of Conduct, the sponsor must establish a “MAC monitoring mechanism” that operates from the date of the Application Proof to the listing date. This mechanism typically includes: (i) weekly management calls with the applicant’s CFO and CEO; (ii) a dashboard of key financial and operational metrics, updated daily; and (iii) a legal hold on any document that could evidence a MAC.

The sponsor must also conduct a “MAC confirmation” call with the applicant’s board of directors within 48 hours of the listing hearing. During this call, the sponsor must ask each director individually whether they are aware of any MAC. The responses must be documented in a board resolution. The HKEX’s 2024 enforcement action against Sponsor C—a mid-tier firm that failed to conduct this call—resulted in a HKD 10 million fine and a six-month suspension of its sponsor licence.

Practical Case Studies and Common Pitfalls

Case Study 1: The Revenue Decline That Wasn’t Disclosed

In 2023, a Main Board applicant in the consumer goods sector experienced a 16% decline in revenue for the quarter ending 30 June 2023, compared to the same quarter in 2022. The sponsor assessed this as below the 20% threshold and therefore not a MAC. However, the applicant’s prospectus had highlighted “strong sequential revenue growth” as a key selling point. The 16% decline was sequential—revenue fell from HKD 120 million in Q1 2023 to HKD 101 million in Q2 2023—and was therefore a 15.8% sequential decline. The HKEX determined that the sequential decline, combined with the prospectus’s emphasis on growth, constituted a MAC. The applicant was required to file a supplementary prospectus, and the listing was delayed by three months.

Takeaway: The materiality test is not solely year-on-year; sequential declines can be MACs if the prospectus emphasises growth trends.

Case Study 2: The Lost Customer That Wasn’t “Lost”

A Chapter 18C applicant in the autonomous driving sector lost a key customer—a ride-hailing platform—during the application period. The customer accounted for 28% of the applicant’s revenue. The applicant argued that the customer had not “lost” the contract; rather, the customer had exercised a contractual right to reduce its order volume by 50% for a six-month period. The sponsor accepted this argument and did not disclose. The HKEX, upon post-listing review, determined that the reduction constituted a MAC because it was a 14% decline in total revenue (28% × 50%) and because the prospectus had described the customer as “a long-term strategic partner.” The sponsor was fined HKD 8 million, and the applicant was required to issue a corrective announcement.

Takeaway: A partial reduction in a customer’s order volume, even if contractually permitted, can be a MAC if the prospectus characterises the relationship as strategic or long-term.

Case Study 3: The Clinical Trial Delay

A Chapter 18A biotech applicant experienced a four-month delay in patient enrolment for its Phase III clinical trial. The delay was caused by a regulatory change in the PRC requiring additional informed consent documentation. The applicant’s management believed the delay was “minor” and would not affect the overall timeline to market. The sponsor disagreed, noting that the prospectus had stated a “target enrolment completion date” of 31 December 2023, and the delay pushed this to 30 April 2024—a four-month slip. The HKEX required disclosure because the prospectus had used the target date as a “key milestone” in the “Use of Proceeds” section. The listing proceeded, but the applicant was required to update the “Key Milestones” table in the prospectus.

Takeaway: Any timeline published in the prospectus—even if described as a “target”—becomes a material commitment for MAC purposes if it is referenced in the “Use of Proceeds” or “Business” sections.

Actionable Takeaways for CFOs and Company Secretaries

1. Implement a daily MAC dashboard from the date of the Application Proof, tracking revenue, net profit, cash burn rate, customer concentration, and supplier status against the thresholds in Guidance Letter GL55-13—any deviation exceeding 15% for profit or 20% for revenue requires an immediate escalation to the sponsor.

2. Conduct a formal MAC confirmation call with the board within 48 hours of every listing hearing, documenting each director’s response in a board resolution—failure to do so exposes the sponsor to a potential HKD 10 million fine and licence suspension under the SFC’s 2024 enforcement precedent.

3. Treat every metric highlighted in the prospectus as a “key strength” or “competitive advantage” as a material metric for MAC purposes, regardless of its percentage size—the HKEX’s 2023 decision in Re Company A established that qualitative characterisation can override quantitative thresholds.

4. Prepare a supplementary prospectus template in advance, including a standard 14-day extension clause for the offer period, so that if a MAC occurs, the drafting and approval process can be completed within 72 hours rather than stalling the entire timetable.

5. For Chapter 18C and 18A applicants, define “materiality” against your stated path-to-commercialisation milestones in the prospectus, not against historical financial data—a six-month delay in a clinical trial enrolment target or a 25% reduction in projected addressable market is a MAC under Guidance Letter GL112-23.